LOUVAIN-LA-NEUVE: Penn Medicine and IBA announced Monday the creation of Noventra Oncology Alliance, a joint venture aimed at helping health care providers develop, implement and operate proton therapy and advanced radiation oncology programs.

The new company will offer integrated services including strategic and financial planning, clinical readiness, program implementation and long-term operational support, according to the announcement.

The venture combines Penn Medicine’s clinical, operational, research and education expertise with IBA’s proton therapy technology and project development capabilities. It is intended to help health care organizations manage the complexities of building and sustaining proton therapy programs.

Proton therapy has become an increasingly important part of comprehensive cancer care, and health systems worldwide are seeking to expand access while maintaining clinical excellence and financial sustainability, the companies said. But developing and operating a successful program requires more than buying equipment. Organizations must address strategic planning, capital investment, reimbursement, workforce development, clinical readiness, operational performance, research infrastructure and long-term growth.

“By combining Penn Medicine’s decades of experience building and operating one of the world’s leading proton therapy programs with IBA’s expertise in proton therapy technology and implementation, we are creating a unique platform to help healthcare organizations deliver exceptional care to patients while building sustainable, high-performing oncology programs,” said Dr. James Metz, chair of radiation oncology at the University of Pennsylvania Perelman School of Medicine.

Henri de Romrée, deputy CEO of IBA, said a center that cannot treat patients at scale or operate sustainably ultimately falls short of its purpose. He said the venture helps organizations reduce the clinical, operational and financial risks of developing advanced radiation oncology programs.

“It will also be key to reinforcing the value of this technology in cancer treatment and accelerating its broader adoption,” de Romrée said.

Unlike traditional advisory models, the joint venture combines the perspectives of a leading clinical operator and a global proton therapy technology company, offering a single partner from initial strategy through long-term operations, the companies said.

More information about Noventra’s services is available at the company’s website or at IBA’s booth (#843) and Penn Medicine’s booth (#1722) during the ASTRO Annual Meeting 2026 in Boston.

—

**About Penn Medicine**

Penn Medicine is one of the world’s leading academic medical centers, dedicated to medical education, biomedical research, patient care and community service. It consists of the University of Pennsylvania Health System and the Perelman School of Medicine, founded in 1765 as the nation’s first medical school.

The Perelman School of Medicine is consistently among the top recipients of National Institutes of Health funding, with $550 million awarded in fiscal 2022. Penn Medicine teams have pioneered discoveries including CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.

The health system’s facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. They include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health and Pennsylvania Hospital, the nation’s first hospital, founded in 1751.

Penn Medicine is an $11.1 billion enterprise with more than 49,000 faculty and staff.

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology and the leading supplier of equipment and services in proton therapy, industrial sterilization, radiopharmaceuticals and dosimetry. Based in Louvain-la-Neuve, Belgium, the company employs about 2,300 people worldwide and is a certified B Corporation. IBA is listed on Euronext.